Radioquimioterapia concurrente en pacientes con tumores digestivos localmente avanzados y diseminados

Carraro, Silvia; Roca, Enrique Luis; Castillo Odena, María del Socorro; Sardi, Mabel; Rafailovici, Luisa; Rodríguez, María Cristina; Ballarino, Graciela; González, Guillermo.
Oncol. clín ; 2(3): 37-40, sept. 1997. tab
Artículo en Español | BINACIS | ID: bin-7471

Documentos relacionados

  1. [Primary appendiceal signet ring cell carcinoma:a case report].
  2. Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial.
  3. The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
  4. Phase I trial of apatinib and paclitaxel+oxaliplatin+5-FU/levoleucovorin for treatment-naïve advanced gastric cancer.
  5. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
  6. Cost-Effectiveness Analysis of FOLFIRI-Based First-Line Regimens for Metastatic Colorectal Cancer Using Clinical Decision Analysis.
  7. [A Case of Consciousness Disorder Due to Hyperammonemia Induced by Modified FOLFOX6 for Multiple Liver Metastasis from Rectal Cancer].
  8. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
  9. Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin.
  10. High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy.